4,968 Eli Lilly and Company $LLY Shares Acquired by Global Wealth Management Investment Advisory Inc.

Global Wealth Management Investment Advisory Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 109.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,496 shares of the company’s stock after purchasing an additional 4,968 shares during the quarter. Eli Lilly and Company accounts for about 1.4% of Global Wealth Management Investment Advisory Inc.’s portfolio, making the stock its 19th largest position. Global Wealth Management Investment Advisory Inc.’s holdings in Eli Lilly and Company were worth $10,987,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. 71 West Capital Partners increased its stake in Eli Lilly and Company by 1.7% in the 3rd quarter. 71 West Capital Partners now owns 6,024 shares of the company’s stock worth $6,970,000 after buying an additional 102 shares during the period. Nemes Rush Group LLC lifted its holdings in Eli Lilly and Company by 0.6% during the 3rd quarter. Nemes Rush Group LLC now owns 15,668 shares of the company’s stock valued at $18,129,000 after buying an additional 93 shares in the last quarter. Pinion Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 5.4% during the 3rd quarter. Pinion Investment Advisors LLC now owns 1,454 shares of the company’s stock valued at $1,682,000 after buying an additional 75 shares in the last quarter. Montis Financial LLC lifted its holdings in Eli Lilly and Company by 21.2% during the 3rd quarter. Montis Financial LLC now owns 360 shares of the company’s stock valued at $417,000 after buying an additional 63 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc boosted its position in Eli Lilly and Company by 1.0% in the 3rd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 81,803 shares of the company’s stock valued at $94,653,000 after buying an additional 777 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 4.4%

Shares of Eli Lilly and Company stock opened at $1,413.22 on Tuesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The firm’s 50-day moving average is $1,220.13 and its two-hundred day moving average is $1,102.83. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.87, a PEG ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter last year, the firm posted $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LLY shares. Citigroup upped their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,650.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.